A Phase I, Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 in Refractory Solid Tumor Patients.
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2014
At a glance
- Drugs L-DOS 47 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 11 Apr 2014 Status changed from not yet recruiting to discontinued.
- 14 Jun 2012 Helix BioPharma has decided not to start this trial until results from its Polish phase I/II trial have been reported according to a Helix BioPharma media release.
- 05 Mar 2012 Status changed from recruiting to not yet recruiting.